Alcami Corporation, a US-based contract development and manufacturing organisation (CDMO), announced on Monday that it has acquired a 37,000-square-foot facility at 4620 Creekstone Drive in Durham, North Carolina.

This USD6.7m investment is intended to strengthen Alcami's presence in the Research Triangle region and support its continued expansion of advanced laboratory services.

Located in the heart of Research Triangle Park (RTP), the two-storey facility will serve as a hub for Alcami's growing analytical and development capabilities. In October, Alcami announced plans for a major lab expansion at this site, scheduled for completion later this year. This expansion will enhance Alcami's ability to support a broad range of complex therapeutics, including biologics, peptides, proteins, oligonucleotides, and cell and gene therapy drug substances.

"This acquisition marks another milestone in our strategy to deliver innovative, scalable solutions for our clients in the growing area of biologics," said Katie Schlipp, at Alcami president, Lab Operations. "By expanding our analytical lab capabilities in RTP, we're able to support innovators in bringing life-changing therapies to patients faster and more reliably."